ClinVar Miner

Submissions for variant NM_000384.3(APOB):c.4796G>T (p.Arg1599Leu)

dbSNP: rs746414462
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000494563 SCV000581921 uncertain significance not provided 2017-05-08 criteria provided, single submitter clinical testing A variant of uncertain significance has been identified in the APOB gene. The R1599L variant has not been published as pathogenic or been reported as benign to our knowledge. This variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The R1599L variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. In addition, this substitution occurs at a position that is conserved in mammals. Moreover, in silico analysis predicts this variant is probably damaging to the protein structure/function. Nevertheless, no missense variants in nearby residues have been reported in the Human Gene Mutation Database in association with FH (Stenson et al., 2014).
Ambry Genetics RCV003302727 SCV004000637 uncertain significance Cardiovascular phenotype 2023-03-20 criteria provided, single submitter clinical testing The p.R1599L variant (also known as c.4796G>T), located in coding exon 26 of the APOB gene, results from a G to T substitution at nucleotide position 4796. The arginine at codon 1599 is replaced by leucine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Invitae RCV003766769 SCV004608933 likely benign Hypercholesterolemia, autosomal dominant, type B; Familial hypobetalipoproteinemia 1 2023-01-27 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.